General Toxicity Notes
Anticholinergic side effects cause urinary retention and orthostatic hypotension. Drug may cause confusion and excessive sedation.
Excreted Unchanged %
Hepatic
Half-Life (Normalesrd) Hours
12-24/No data
Plasma Protein Binding %
96
Volume Of Distribution L/Kg
10-20
Dose For Normal Renal Function
25 mg q8h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [A]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
Bickel MH, Raaflaub RM, Hellmü ller M, Stauffer EJ. Characterization of drug distribution and binding competition by two-chamber and multi-chamber distribution dialysis. J Pharm Sci. 1987; 76: 68-74. [PMID: 3585729] / el-Yazigi A, Chaleby K. Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison. Psychopharmacology (Berl). 1988; 95: 63-7. [PMID: 3133701] / Lieberman JA, Cooper TB, Suckow RF, Steinberg H, Borenstein M, Brenner R, et al. Tricyclic antidepressant and metabolite levels in chronic renal failure. Clin Pharmacol Ther. 1985; 37: 301-7. [PMID: 3971655] / Sallee FR, Pollock BG. Clinical pharmacokinetics of imipramine and desipramine. Clin Pharmacokinet. 1990; 18: 346-64. [PMID: 2185906]